Amgen Inc. $AMGN Stock Holdings Increased by Landscape Capital Management L.L.C.

Key Points

• Landscape Capital Management L.L.C. increased its position in Amgen Inc. by 74.0% during Q1, now holding 9,239 shares valued at approximately $2.88 million.
• Amgen's recent quarterly earnings topped estimates, reporting $6.02 EPS and $9.18 billion in revenue, indicating a 9.4% year-over-year growth.
• Amgen declared a quarterly dividend of $2.38 per share, with an annual yield of 3.3% and a payout ratio of 77.84%.

Landscape Capital Management L.L.C. lifted its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 74.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,239 shares of the medical research company's stock after buying an additional 3,929 shares during the quarter. Landscape Capital Management L.L.C.'s holdings in Amgen were worth $2,878,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Continuum Advisory LLC raised its stake in shares of Amgen by 0.7% in the fourth quarter. Continuum Advisory LLC now owns 5,154 shares of the medical research company's stock worth $1,343,000 after purchasing an additional 35 shares during the last quarter. Octavia Wealth Advisors LLC raised its stake in shares of Amgen by 1.5% during the 1st quarter. Octavia Wealth Advisors LLC now owns 2,435 shares of the medical research company's stock worth $759,000 after buying an additional 35 shares during the period. Affinity Capital Advisors LLC raised its stake in shares of Amgen by 4.5% during the 1st quarter. Affinity Capital Advisors LLC now owns 861 shares of the medical research company's stock worth $246,000 after buying an additional 37 shares during the period. Accredited Investors Inc. boosted its stake in shares of Amgen by 1.7% in the first quarter. Accredited Investors Inc. now owns 2,164 shares of the medical research company's stock worth $674,000 after acquiring an additional 37 shares during the last quarter. Finally, Rockline Wealth Management LLC boosted its stake in shares of Amgen by 3.2% in the first quarter. Rockline Wealth Management LLC now owns 1,240 shares of the medical research company's stock worth $386,000 after acquiring an additional 38 shares during the last quarter. Institutional investors own 76.50% of the company's stock.

Amgen Trading Down 0.3%

Shares of AMGN stock traded down $0.99 during mid-day trading on Tuesday, hitting $286.72. 975,118 shares of the company's stock were exchanged, compared to its average volume of 2,793,032. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $339.17. The stock has a 50-day simple moving average of $293.44 and a two-hundred day simple moving average of $292.85. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24. The stock has a market cap of $154.36 billion, a price-to-earnings ratio of 23.40, a PEG ratio of 2.50 and a beta of 0.49.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, beating analysts' consensus estimates of $5.28 by $0.74. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm had revenue of $9.18 billion for the quarter, compared to analysts' expectations of $8.86 billion. During the same quarter last year, the firm earned $4.97 earnings per share. The firm's revenue for the quarter was up 9.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. Equities analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 12th. Shareholders of record on Friday, August 22nd will be paid a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date is Friday, August 22nd. Amgen's payout ratio is currently 77.84%.

Analyst Upgrades and Downgrades

AMGN has been the topic of a number of research analyst reports. Piper Sandler lifted their target price on Amgen from $328.00 to $342.00 and gave the company an "overweight" rating in a research report on Monday, August 25th. William Blair restated an "outperform" rating on shares of Amgen in a report on Tuesday, June 24th. Guggenheim started coverage on Amgen in a research report on Tuesday, May 20th. They set a "neutral" rating and a $288.00 price objective for the company. Cantor Fitzgerald reissued a "neutral" rating and issued a $305.00 target price on shares of Amgen in a research report on Tuesday, June 24th. Finally, Citigroup upped their price objective on Amgen from $305.00 to $310.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $304.43.

Insider Transactions at Amgen

In other news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total transaction of $376,286.33. Following the sale, the senior vice president directly owned 7,209 shares of the company's stock, valued at approximately $2,141,000.91. The trade was a 14.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Rachna Khosla sold 1,500 shares of the business's stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the sale, the senior vice president directly owned 8,162 shares of the company's stock, valued at approximately $2,364,368.16. This represents a 15.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.69% of the company's stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.